Shares of Ultragenyx Pharmaceutical (RARE) plummeted 5.10% during Thursday's trading session, following a target price cut by Citigroup. The significant drop has caught the attention of investors and analysts alike, as the biotech company faces renewed scrutiny.

Citigroup, a major financial services firm, revised its target price for Ultragenyx Pharmaceutical, lowering it from $110 to $103. While the new target still represents potential upside from the current trading price, the reduction has sparked concerns among market participants. The adjustment in the target price suggests that Citigroup analysts may have reassessed their outlook on the company's future performance or market conditions.

Ultragenyx Pharmaceutical, known for developing and commercializing novel products for the treatment of rare and ultra-rare genetic diseases, now faces increased pressure to demonstrate its growth potential. Investors will likely be watching closely for any updates on the company's drug pipeline, clinical trial results, or financial performance that could justify a more optimistic outlook. As the biotech sector continues to be volatile, this price movement underscores the sensitivity of pharmaceutical stocks to analyst recommendations and market sentiment.